(R)-(-)-Deprenyl hydrochloride

Discontinued Product

1095 has been discontinued.

View all Monoamine Oxidases products.
Description: MAO-B inhibitor
Alternative Names: Selegiline
Chemical Name: (R)-(-)-N-α-Dimethyl-N-2-propynylbenzeneethanamine hydrochloride
Purity: ≥99% (HPLC)
Datasheet
Citations
Reviews
Literature (3)

Biological Activity for (R)-(-)-Deprenyl hydrochloride

(R)-(-)-Deprenyl hydrochloride is a selective inhibitor of monoamine oxidase B (MAO-B).

Technical Data for (R)-(-)-Deprenyl hydrochloride

M. Wt 223.74
Formula C13H17N.HCl
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 14611-52-0
PubChem ID 26758
InChI Key IYETZZCWLLUHIJ-UTONKHPSSA-N
Smiles C#CCN(C)[C@H](C)CC1=CC=CC=C1.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for (R)-(-)-Deprenyl hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for (R)-(-)-Deprenyl hydrochloride

References are publications that support the biological activity of the product.

Gerlach et al (1992) The molecular pharmacology of L-deprenyl. Eur.J.Pharmacol. 226 97 PMID: 1639115

Kaseda et al (1999) Effect of selegeline on DA concentration in the striatum of a primate. Brain Res. 815 44 PMID: 9974121

Kotake et al (1998) Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1,2,3,4-tetrahydroisoquinoline in mice: in vivo and in vitro studies. Brain Res. 787 341 PMID: 9518683

Mercuri et al (1998) Modification of lev. responses by deprenyl (selegiline): an electrophysiological and behavioural study in the rat relevant to Parkinson's disease. Ann.Neurol. 43 613 PMID: 9585355

Merck Index 12 8569

View Related Products by Product Action

View all Monoamine Oxidase Inhibitors

Keywords: (R)-(-)-Deprenyl hydrochloride, (R)-(-)-Deprenyl hydrochloride supplier, MAO-B, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, parkinson's, parkinsons, Selegiline, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 1095, Tocris Bioscience

Citations for (R)-(-)-Deprenyl hydrochloride

Citations are publications that use Tocris products.

Currently there are no citations for (R)-(-)-Deprenyl hydrochloride.

Reviews for (R)-(-)-Deprenyl hydrochloride

There are currently no reviews for this product. Be the first to review (R)-(-)-Deprenyl hydrochloride and earn rewards!

Have you used (R)-(-)-Deprenyl hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.